<DOC>
	<DOC>NCT01219114</DOC>
	<brief_summary>The purpose of this study is to monitor the safety and efficacy of CUBICIN under conditions of actual use in patients who are diagnosed with complicated Skin and Skin Structure infection (cSSI) or Staphylococcus aureus bacteria including right-sided endocarditis and are prescribed CUBICIN by their physician.</brief_summary>
	<brief_title>Safety and Efficacy Study of CUBICIN (Daptomycin) Under Conditions of Actual Use</brief_title>
	<detailed_description />
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Endocarditis</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<criteria>Diagnosis of cSSSI known or suspected to be due to grampositive bacteria Diagnosis of rightsided endocarditis with one or more positive culture for S. aureus within two days prior to initiation of medication Prescribed daptomycin by patient's attending physician Known allergic or serious adverse reaction to daptomycin Patients with pneumonia Patients with baseline CPK values &gt;1000 U/L or 5x ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Daptomycin</keyword>
	<keyword>endocarditis</keyword>
	<keyword>complicated skin and skin structure infection</keyword>
</DOC>